JMP Securities analyst Silvan Tuerkcan downgraded Intellia Therapeutics to Market Perform from Outperform without a price target. The analyst views the shares as fairly valued at current levels. Moving in-vivo editing to the U.S. will represent a major milestone, but there is little upside for the stock with more downside risk as the company engages regulators, Tuerkcan tells investors in a research note. The analyst says 2023 will bring little in terms of clinical updates for Intellia with the focus on regulatory interactions.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics downgraded to Market Perform from Outperform at JMP Securities
- Intellia awarded innovation passport in UK for NTLA-2002
- Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
- ZM, NTLA, or SQ: Which Cathie Wood ARKK Stock Is Most Appealing in 2023?
- Intellia Therapeutics highlights strategic priorities, milestones for 2023